'

Epigral held a conference call on 05 May 2025 to discuss the results for the quarter ended March 2025 and way forward. Mr. Maulik Patel - Chairman & Managing Director, Mr. Kaushal Soparkar - Executive Director, Mr. Sanjay Jain - Chief Financial Officer and Mr. Milind Kotecha - Investor Relations of the company addressed the call.

Highlights of the Concall

• The company mentioned that overall the chemical industry is witnessing some sort of a growth in a few selected products portfolio and a few products basket but the growth is still at a slower pace meaning chemical industry movement is product specific and region specific in terms of growth.

• Epigral revenue grew by 20% YoY in Q4FY25 to Rs 631 crore, on account volume growth from derivative products led by substantial capex in recent past. Revenue contribution from derivatives & specialty business increased to 52% in Q4FY25 vs 48% in Q4FY24.

• Epigral EBITDA grew by 12% to Rs 173 crore...
  
  
  
  Pleaselogin & subscribe to view the full report.
  
  More Reports
  • 

    (05-Feb-2025)

    Castrol India

    Expects EBITDA margin of 22%-25% for CY25
  • 

    (10-Feb-2023)

    Deepak Nitrite

    Plans capex of about Rs 1500 crore for FY23 and FY24
  • 

    (09-Feb-2023)

    Mayur Uniquoters

    Targets revenue of Rs 1000 crore in FY24
  • 

    (31-Jan-2023)

    Tega industries

    Capex plan is US$ 30-32 million for next three years